

BEYOND MEDICAL TECHNOLOGIES INC.
(formerly Micron Waste Technologies Inc.)

**Suite 206 – 1045 West 8th Avenue
Vancouver, BC V6H 1C3
Telephone: (604) 805-4602
email: info@beyondmd.ca**

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that an In Person/Teleconference Call Annual General Meeting (the “**Meeting**”) of the Shareholders of Beyond Medical Technologies Inc. (the “**Company**”) will be held at 1500 – 1055 West Georgia Street, Vancouver, British Columbia on February 28, 2022 at 10:00 a.m. (Pacific Time).

The Company will offer Shareholders the option to listen and participate (but not vote) at the Meeting in real time by conference call at the following co-ordinates:

**Canada Toll Free: 1 855 244 8677
US Toll Free: 1 855 282 6330
Access Code: 95400309**

Due to ongoing concerns related to the current COVID-19 pandemic (“**COVID-19**”), rather than attend the Meeting in person, the Company strongly encourages Shareholders to submit their votes by proxy in advance of the Meeting by sending in the completed form of Proxy included with this Notice well before **10:00 a.m. (Pacific Time) on Thursday, February 24, 2022** (the “**Proxy Deadline**”).

Shareholders who wish to attend the Meeting in person must call the Company at (604) 805-4602 or email to info@beyondmd.ca to inform of their intention to attend in person at least 48 hours prior to the Meeting for further instructions on in-person attendance procedures.

The Meeting will be held for the following purposes:

1. to receive and consider the audited financial statements of the Company for the financial years ended December 31, 2020 and 2019, the report of the auditor thereon and the related management discussion and analysis (together, the “*Financial Statements*”) (see “*Financial Statements*” in the Circular);
2. to elect Directors of the Company for the ensuing year (see “*Election of Directors*” in the Circular);
3. to appoint Smythe LLP, Chartered Professional Accountants, as Auditor for the Company for the ensuing year and authorize the Directors to determine the Auditor’s remuneration (see “*Appointment of Auditor*” in the Circular); and
4. to consider, and if though appropriate, pass an ordinary resolution approving, ratifying and confirming the Company’s Stock Option Plan for continuation until the next annual meeting of shareholders (see “*Approval of Stock Option Plan*” in the Circular).

No other matters are contemplated for consideration at the Meeting; however any permitted amendment to or variation of any matter identified in this Notice may properly be considered at the Meeting. The Meeting may also consider the transaction of such other business as may properly come before the Meeting or any adjournment thereof.

NOTE OF CAUTION CONCERNING COVID-19

*At the date of this Notice and the accompanying Information Circular it is the intention of the Company to hold the Meeting at the location stated above in this Notice. We are continuously monitoring development of the current coronavirus (COVID-19) outbreak (“**COVID-19**”). In light of the rapidly evolving public health guidelines related to COVID-19, we ask shareholders to consider voting their shares by proxy and **NOT** attend the meeting in person. Those shareholders who do wish to attend the Meeting in person, should carefully consider and follow the instructions of the federal Public Health Agency of Canada available at: <https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19.html>. We ask that shareholders also review and follow the instructions of any regional health authorities of the Province of British Columbia, including the Vancouver Coastal Health Authority, the Fraser Health Authority and any other health authority holding jurisdiction over the areas you must travel through to attend the Meeting. Do not attend the Meeting in person if you are experiencing any cold or flu-like symptoms, or if you or someone with whom you have been in close contact has travelled to/from outside of Canada within the 14 days immediately prior to the Meeting. All shareholders are strongly encouraged to vote by submitting their completed form of proxy (or voting instruction form) prior to the Meeting by one of the means described in the Information Circular accompanying this Notice.*

*The Company reserves the right to take any additional precautionary measures deemed to be appropriate, necessary or advisable in relation to the Meeting in response to further developments in the COVID-19 outbreak, including: (i) holding the Meeting virtually or by providing a webcast of the Meeting; (ii) hosting the Meeting solely by means of remote communication; (iii) changing the Meeting date and/or changing the means of holding the Meeting; (iv) denying access to persons who exhibit cold or flu-like symptoms, or who have, or have been in close contact with someone who has travelled to/from outside of Canada within the 14 days immediately prior to the Meeting; (v) **denying access to persons that do not have evidence of full vaccination or a negative COVID-19 rapid test result completed within 24 hours immediately prior to the Meeting**, and (vi) such other measures as may be recommended by public health authorities in connection with gatherings of persons such as the Meeting. Should any such changes to the Meeting format occur, the Company will announce any and all of these changes by way of news release, which will be filed under the Company’s profile on SEDAR. We strongly recommend you check the Company’s SEDAR profile prior to the Meeting for the most current information. In the event of any changes to the Meeting format due to the COVID-19 outbreak, the Company will **NOT** prepare or mail amended Meeting Proxy Materials.*

The Company has elected to use the notice-and-access provisions under National Instrument 51-102 – *Continuous Disclosure Obligations* (“NI 51-102”), in the case of mailing to registered Shareholders, and section 2.7.1 of National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* (“NI 54-101”), in the case of beneficial Shareholders (“**Notice-and-Access Provisions**”) for this Meeting. Notice-and-Access Provisions are a set of rules developed by the Canadian Securities Administrators that allow a Company to reduce the volume of materials to be physically mailed to Shareholders by posting the Information Circular and any additional annual meeting materials online. Shareholders will still receive this Notice of Meeting and a form of proxy and may choose to receive a hard copy of the Information Circular. The Company will not use procedures known as ‘stratification’ in relation to the use of Notice-and-Access Provisions. Stratification occurs when a reporting issuer using the Notice-and-Access Provisions provides a paper copy of the Circular to some shareholders with a notice package. In relation to the Meeting, all Shareholders will receive the required documentation under the Notice-and-Access Provisions, which will not include a paper copy of the Information Circular.

Copies of this Notice of Meeting, the Information Circular, the Proxy (together “Proxy Materials”) and the audited financial statements, the auditor’s report and related MD&A, are posted on the Company’s website at

<https://www.beyondmd.ca/investors/AGM/> and are filed on SEDAR under the Company's profile at www.sedar.com. Any Shareholder who wishes to receive a paper copy of the Information Circular, should contact the Company at Suite 206 – 1045 West 8th Avenue, Vancouver, BC V6H 1C3 or by telephoning the Company at (604) 805-4602 or toll-free at 1-844-318-8216. A Shareholder may also use the toll-free number noted to obtain additional information about the Notice-and-Access Provisions.

To allow for reasonable time to be allotted for a Shareholder to receive and review a paper copy of the Information Circular and submit their vote prior to **10:00 a.m. (Pacific Time) on Thursday, February 24, 2022** (the "**Proxy Deadline**"), any Shareholder wishing to request a paper copy of the Information Circular as described above, should ensure such request is received by **February 9, 2022**. Under Notice-and-Access Provisions, Proxy Materials will be available for viewing for up to one (1) year from the date of posting and a paper copy of the materials can be requested at any time during this period.

The Circular contains details of matters to be considered at the Meeting, and a copy is posted for viewing on the Company's website at <https://www.beyondmd.ca/investors/investor-package/>. **Please review the Circular before voting.**

Registered shareholders who are unable to attend the Meeting in person and who wish to ensure that their Common Shares will be voted at the Meeting are requested to complete, date and sign the enclosed form of proxy, or another suitable form of proxy, and deliver it in accordance with the instructions set out in the form of proxy and in the Circular.

A non-registered shareholder (also a "Beneficial Shareholder") who plans to attend the Meeting must follow the instructions set out in the form of proxy (or voting instruction form) accompanying this Notice and in the Circular, to ensure that such shareholder's Common Shares will be voted at the Meeting. If you hold your Common Shares in a brokerage account you are not a registered shareholder.

The audited financial statements for the financial years ended December 31, 2020 and 2019, the report of the auditor thereon, and related management discussion and analysis will be made available at the Meeting and are available on www.sedar.com.

DATED at Vancouver, British Columbia, as at January 14, 2022.

BY ORDER OF THE BOARD

"Kulwant Malhi"

Kulwant Malhi
Chairman, Chief Executive Officer and Director